Literature DB >> 12181170

Physiological and morphological effects of alendronate on rabbit esophageal epithelium.

A Dobrucali1, N A Tobey, M S Awayda, C Argote, S Abdulnour-Nakhoul, W Shao, R C Orlando.   

Abstract

Alendronate, an aminobisphosphonate, produces as a side effect a topical (pill induced) esophagitis. To gain insight into this phenomenon, we assessed the effects of luminal alendronate on both esophageal epithelial structure and function. Sections of rabbit esophageal epithelium were exposed to luminal alendronate at neutral or acidic pH while mounted in Ussing chambers to monitor transmural electrical potential difference (PD), short-circuit current (I(sc)), and resistance (R). Morphological changes were sought by light microscopy in hematoxylin and eosin-stained sections. Impedance analysis was used for localization of alendronate-induced effects on ion transport. Luminal, but not serosal, alendronate (pH 6.9-7.2), increased PD and I(sc) in a dose- and time-dependent manner, with little change in R and mild edema of surface cell layers. The changes in I(sc) (and PD) were reversible with drug washout and could be prevented either by inhibition of Na,K-ATPase activity with serosal ouabain or by inhibition of apical Na channels with luminal acidification to pH 2.0 with HCl. An effect on apical Na channel activity was also supported by impedance analysis. Luminal alendronate at acidic pH was more damaging than either alendronate at neutral pH or acidic pH alone. These data suggest that alendronate stimulates net ion (Na) transport in esophageal epithelium by increasing apical membrane sodium channel activity and that this occurs with limited morphological change and no alteration in barrier function. Also alendronate is far more damaging at acidic than at neutral pH, suggesting its association with esophagitis requires gastric acid for expression. This expression may occur either by potentiation between the damaging effects of (refluxed) gastric acid and drug or by acid-induced conversion of the drug to a more toxic form.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181170     DOI: 10.1152/ajpgi.00014.2002

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  9 in total

Review 1.  A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation.

Authors:  Maria Luisa Brandi; Dennis Black
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

Review 2.  Fracture mortality: associations with epidemiology and osteoporosis treatment.

Authors:  Sebastian E Sattui; Kenneth G Saag
Journal:  Nat Rev Endocrinol       Date:  2014-08-05       Impact factor: 43.330

3.  Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study.

Authors:  J-H Kang; J J Keller; H-C Lin
Journal:  Osteoporos Int       Date:  2012-11-14       Impact factor: 4.507

4.  Pill Esophagitis.

Authors:  Nathaniel S. Winstead; Robert Bulat
Journal:  Curr Treat Options Gastroenterol       Date:  2004-02

5.  Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

Authors:  Cathleen S Colón-Emeric; Peter Mesenbrink; Kenneth W Lyles; Carl F Pieper; Steven Boonen; Pierre Delmas; Erik F Eriksen; Jay Magaziner
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

6.  A novel inhibitory mechanism of nitrogen-containing bisphosphonate on the activity of Cl- extrusion in osteoclasts.

Authors:  Kimiko Ohgi; Hiroshi Kajiya; Fujio Okamoto; Yoshiyuki Nagaoka; Tokuya Onitsuka; Atsushi Nagai; Ryuji Sakagami; Koji Okabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-06       Impact factor: 3.000

7.  Alendronate effect in esophagus, stomach and liver: an animal based pathological study.

Authors:  Theodora Papamitsou; Sotiris Sotiriou; Apostolos Papakoulas; Alexandros Toskas; Dimitrios Kamperis; Sofia Karachrysafi; Eva-Maria Dietrich; Stergios Lialiaris; Antonia Sioga
Journal:  Histol Histopathol       Date:  2019-09-10       Impact factor: 2.303

Review 8.  A critical review of brand and generic alendronate for the treatment of osteoporosis.

Authors:  Jacques P Brown; Kenneth S Davison; Wojciech P Olszynski; Karen A Beattie; Jonathan D Adachi
Journal:  Springerplus       Date:  2013-10-21

9.  Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition.

Authors:  Claudia Gómez Acotto; Carlos Antonelli; Damien Flynn; Dennis McDaid; Emilio J A Roldán
Journal:  Calcif Tissue Int       Date:  2012-08-26       Impact factor: 4.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.